Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 14
- Registration Number
- NCT03393611
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 122
- Registration Number
- NCT03385096
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients
- Conditions
- Interventions
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT03352765
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT03346135
- Locations
- 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03342196
- Locations
- 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
ASCT With Nivolumab in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT03292263
- Locations
- 🇷🇺
Boris V Afanasyev, MD, Prof., Saint Petersburg, Russian Federation
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03259503
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Nivolumab With Chemotherapy in Refractory MDS
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 2
- Registration Number
- NCT03259516
- Locations
- 🇷🇺
First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Conditions
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 220
- Registration Number
- NCT03217812
- Locations
- 🇭🇰
Queen Mary Hospital University of Hong Kong, Hong Kong, Hong Kong
🇰🇷Ulsan University Hospital, Ulsan, Korea, Republic of
🇲🇾Hospital Ampang, Ampang, Malaysia
MUK Nine b: OPTIMUM Treatment Protocol
- Conditions
- Interventions
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 95
- Registration Number
- NCT03188172
- Locations
- 🇬🇧
Bristol Haematology & Oncology Centre, Bristol, United Kingdom
🇬🇧Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Birmingham Heartlands Hospital, Birmingham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.